Cross-Neutralizing Antibodies to Pandemic 2009 H1N1 and Recent Seasonal H1N1 Influenza A Strains Influenced by a Mutation in Hemagglutinin Subunit 2


Pandemic 2009 H1N1 influenza A virus (2009 H1N1) differs from H1N1 strains that circulated in the past 50 years, but resembles the A/New Jersey/1976 H1N1 strain used in the 1976 swine influenza vaccine. We investigated whether sera from persons immunized with the 1976 swine influenza or recent seasonal influenza vaccines, or both, neutralize 2009 H1N1. Using retroviral pseudovirions bearing hemagglutinins on their surface (HA-pseudotypes), we found that 77% of the sera collected in 1976 after immunization with the A/New Jersey/1976 H1N1 swine influenza vaccine neutralized 2009 H1N1. Forty five percent also neutralized A/New Caledonia/20/1999 H1N1, a strain used in seasonal influenza vaccines during the 2000/01–2006/07 seasons. Among adults aged 48–64 who received the swine influenza vaccine in 1976 and recent seasonal influenza vaccines during the 2004/05–2008/09 seasons, 83% had sera that neutralized 2009 H1N1. However, 68% of age-matched subjects who received the same seasonal influenza vaccines, but did not receive the 1976 swine influenza vaccine, also had sera that neutralized 2009 H1N1. Sera from both 1976 and contemporary cohorts frequently had cross-neutralizing antibodies to 2009 H1N1 and A/New Caledonia/20/1999 that mapped to hemagglutinin subunit 2 (HA2). A conservative mutation in HA2 corresponding to a residue in the A/Solomon Islands/3/2006 and A/Brisbane/59/2007 H1N1 strains that circulated in the 2006/07 and 2007/08 influenza seasons, respectively, abrogated this neutralization. These findings highlight a cross-neutralization determinant influenced by a point mutation in HA2 and suggest that HA2 may be evolving under direct or indirect immune pressure.


Vyšlo v časopise: Cross-Neutralizing Antibodies to Pandemic 2009 H1N1 and Recent Seasonal H1N1 Influenza A Strains Influenced by a Mutation in Hemagglutinin Subunit 2. PLoS Pathog 7(6): e32767. doi:10.1371/journal.ppat.1002081
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002081

Souhrn

Pandemic 2009 H1N1 influenza A virus (2009 H1N1) differs from H1N1 strains that circulated in the past 50 years, but resembles the A/New Jersey/1976 H1N1 strain used in the 1976 swine influenza vaccine. We investigated whether sera from persons immunized with the 1976 swine influenza or recent seasonal influenza vaccines, or both, neutralize 2009 H1N1. Using retroviral pseudovirions bearing hemagglutinins on their surface (HA-pseudotypes), we found that 77% of the sera collected in 1976 after immunization with the A/New Jersey/1976 H1N1 swine influenza vaccine neutralized 2009 H1N1. Forty five percent also neutralized A/New Caledonia/20/1999 H1N1, a strain used in seasonal influenza vaccines during the 2000/01–2006/07 seasons. Among adults aged 48–64 who received the swine influenza vaccine in 1976 and recent seasonal influenza vaccines during the 2004/05–2008/09 seasons, 83% had sera that neutralized 2009 H1N1. However, 68% of age-matched subjects who received the same seasonal influenza vaccines, but did not receive the 1976 swine influenza vaccine, also had sera that neutralized 2009 H1N1. Sera from both 1976 and contemporary cohorts frequently had cross-neutralizing antibodies to 2009 H1N1 and A/New Caledonia/20/1999 that mapped to hemagglutinin subunit 2 (HA2). A conservative mutation in HA2 corresponding to a residue in the A/Solomon Islands/3/2006 and A/Brisbane/59/2007 H1N1 strains that circulated in the 2006/07 and 2007/08 influenza seasons, respectively, abrogated this neutralization. These findings highlight a cross-neutralization determinant influenced by a point mutation in HA2 and suggest that HA2 may be evolving under direct or indirect immune pressure.


Zdroje

1. WHO 2009 World now at the start of 2009 influenza pandemic. Available: http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html

2. GartenRJDavisCTRussellCAShuBLindstromS 2009 Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325 197 201

3. DowdleWR 1997 Pandemic influenza: confronting a re-emergent threat. The 1976 experience. J Infect Dis 176 Suppl 1 S69 72

4. HancockKVeguillaVLuXZhongWButlerEN 2009 Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361 1945 1952

5. JohnsMCEickAABlazesDLLeeSEPerdueCL 2010 Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. PLoS One 5 e10722

6. LabrosseBTourdjmanMPorcherRLeGoffJde LamballerieX 2010 Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS One 5 e11036

7. LeeVJTayJKChenMIPhoonMCXieML 2010 Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 28 6852 6857

8. McCullersJAVan De VeldeLAAllisonKJBranumKCWebbyRJ 2010 Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 50 1487 1492

9. CDC 2009 Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009/05/30 ed 521 524

10. SkehelJJWileyDC 2000 Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69 531 569

11. WhiteJMDelosSEBrecherMSchornbergK 2008 Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43 189 219

12. WileyDCWilsonIASkehelJJ 1981 Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289 373 378

13. CatonAJBrownleeGGYewdellJWGerhardW 1982 The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31 417 427

14. OkunoYIsegawaYSasaoFUedaS 1993 A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67 2552 2558

15. KashyapAKSteelJOnerAFDillonMASwaleRE 2008 Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105 5986 5991

16. ThrosbyMvan den BrinkEJongeneelenMPoonLLAlardP 2008 Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3 e3942

17. EkiertDCBhabhaGElsligerMAFriesenRHJongeneelenM 2009 Antibody recognition of a highly conserved influenza virus epitope. Science 324 246 251

18. SuiJHwangWCPerezSWeiGAirdD 2009 Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16 265 273

19. CortiDSuguitanALJrPinnaDSilacciCFernandez-RodriguezBM 2010 Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120 1663 1673

20. WangTTTanGSHaiRPicaNPetersenE 2010 Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6 e1000796

21. WangWButlerENVeguillaVVassellRThomasJT 2008 Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods 153 111 119

22. DolinRWiseTGMazurMHTuazonCUEnnisFA 1977 Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults. J Infect Dis 136 Suppl S435 442

23. WangWXieHYeZVassellRWeissCD 2010 Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J Virol Methods 165 305 310

24. WangWCastelan-VegaJAJimenez-AlbertoAVassellRYeZ 2010 A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology 407 374 380

25. KellyHGrantK 2009 Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14 pii 19288

26. Garcia-GarciaLValdespino-GomezJLLazcano-PonceEJimenez-CoronaAHiguera-IglesiasA 2009 Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 339 b3928

27. TangJWTambyahPAWilder-SmithAPuongKYShawR 2010 Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerg Infect Dis 16 874 876

28. ManicassamyBMedinaRAHaiRTsibaneTStertzS 2010 Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog 6 e1000745

29. EllebedyAHDucatezMFDuanSStigger-RosserERubrumAM 2010 Impact of prior seasonal influenza vaccination and infection on pandemic A(H1N1) influenza virus replication in ferrets. Vaccine 29 3335 3339

30. KashyapAKSteelJRubrumAEstellesABrianteR 2010 Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 6 e1000990

31. WrammertJKoutsonanosDLiGMEdupugantiSSuiJ 2011 Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208 181 193

32. BulloughPAHughsonFMSkehelJJWileyDC 1994 Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371 37 43

33. TempertonNJHoschlerKMajorDNicolsonCManvellR 2007 A sensitive retroviral pseodotype assay for influenza H5N1-neutralizing antibodies. Influenza and Other Respiratory Viruses 1 105 112

34. AlberiniIDel TordelloEFasoloATempertonNJGalliG 2009 Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27 5998 6003

35. KwongPDWilsonIA 2009 HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10 573 578

36. SakabeSIwatsuki-HorimotoKHorimotoTNidomCALeMQ 2010 A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88 249 255

37. LambertLCFauciAS 2010 Influenza vaccines for the future. N Engl J Med 363 2036 2044

38. WeiCJBoyingtonJCMcTamneyPMKongWPPearceMB 2010 Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329 1060 1064

39. WangTTTanGSHaiRPicaNNgaiL 2010 Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 107 18979 18984

40. XuREkiertDCKrauseJCHaiRCroweJEJr 2010 Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328 357 360

41. WeisWIBrungerATSkehelJJWileyDC 1990 Refinement of the influenza virus hemagglutinin by simulated annealing. J Mol Biol 212 737 761

42. WilsonIASkehelJJWileyDC 1981 Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289 366 373

43. NaldiniLBlomerUGallayPOryDMulliganR 1996 In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 263 267

44. ZuffereyRNagyDMandelRJNaldiniLTronoD 1997 Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15 871 875

45. PettersenEFGoddardTDHuangCCCouchGSGreenblattDM 2004 UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25 1605 1612

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2011 Číslo 6
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa